Implanted iPSC-derived thymic organoids
preclinicaldrug program · medium · Thu Dec 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Preserve, restore, or manipulate thymus function to support immune tolerance and increased healthspan, with therapeutic direction toward immune-mediated diseases.
Implanted thymic organoids derived from induced pluripotent stem cells; public patent records describe thymus organoids bioengineered from human pluripotent stem cells.
Tolerance Bio reported completion of a $20.2 million seed round on 2024-12-19 to advance thymus-based therapies for immune-mediated diseases.